Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Gandara D…
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Gandara D…
この記事を読む
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Sys…
この記事を読む
New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter coh…
この記事を読む
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced …
この記事を読む
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian…
この記事を読む
Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 pat…
この記事を読む
Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients…
この記事を読む
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. Marquart J et al. JAMA …
この記事を読む
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Kron A et al …
この記事を読む
Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The developme…